BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/26/2020 2:23:48 AM | Browse: 755 | Download: 823
 |
Received |
|
2020-04-19 22:14 |
|
Peer-Review Started |
|
2020-04-19 22:15 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-05 17:08 |
|
Revised |
|
2020-05-05 18:49 |
|
Second Decision |
|
2020-05-11 13:36 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-05-12 22:49 |
|
Articles in Press |
|
2020-05-12 22:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-05-20 02:18 |
|
Publish the Manuscript Online |
|
2020-05-26 02:23 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Management of hypertension in COVID-19
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Daniel Antwi-Amoabeng, Bryce D Beutler, Alastair E Moody, Zahara Kanji, Nageshwara Gullapalli and Christopher J Rowan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Bryce D Beutler, MD, Doctor, Doctor, Department of Internal Medicine, Reno School of Medicine, University of Nevada, 1155 Mill Street, W-11, Reno, NV 89052, United States. bbeutler@med.unr.edu |
| Key Words |
Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Carvedilol; Coronavirus disease-19; COVID-19; SARS-CoV-2 |
| Core Tip |
The pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2 remain under investigation, but data suggest that the ACE2 receptor plays a central role in infection. It is therefore possible that drugs known to increase ACE2 expression, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers, could promote viral proliferation. Data from animal studies have shown that carvedilol and verapamil attenuate inflammation in viral myocarditis. We are in agreement with the recommendation of major medical societies to maintain angiotensin converting enzyme inhibitor or angiotensin receptor blocker therapy in individuals who are already receiving treatment. However, in the age of coronavirus disease-19, alternative agents should be considered for patients with a new diagnosis of hypertension. |
| Publish Date |
2020-05-26 02:23 |
| Citation |
Antwi-Amoabeng D, Beutler BD, Moody AE, Kanji Z, Gullapalli N, Rowan CJ. Management of hypertension in COVID-19. World J Cardiol 2020; 12(5): 228-230 |
| URL |
https://www.wjgnet.com/1949-8462/full/v12/i5/228.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v12.i5.228 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
